At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 156 enrolled
Drug / intervention
Saxagliptin +3 moredrug
Likely dose
Saxagliptin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients
In Brief
A Phase 3 clinical trial evaluating Saxagliptin, Placebo, and 2 other interventions for Type 2 Diabetes. Completed, enrolled 156 participants across 3 sites.
Detailed Summary
The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedSep 2006
Primary CompletionJan 2008
Study CompletionDec 2009
TodayJul 2026
First PostedSep 12, 2006
Enrollment StartSep 1, 2006
Primary CompletionJan 1, 2008
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.8 years ago
Interventions
Saxagliptindrug
Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
Placebodrug
Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
Metformin (blinded)drug
Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
Metformin (open-label)drug
Tablets, Oral, 500-1500 mg, as needed (starting in LT)